Share Price and Basic Stock Data
Last Updated: December 9, 2025, 8:34 pm
| PEG Ratio | 1.10 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesys International Corporation Ltd operates in the IT Consulting and Software sector, a field characterized by rapid evolution and competition. The company’s revenue trajectory has shown significant momentum, with reported sales rising from ₹120 Cr in FY 2022 to ₹181 Cr in FY 2023, and further to ₹198 Cr in FY 2024. This growth reflects a robust compound annual growth rate (CAGR) that underscores Genesys’s ability to capitalize on shifting market demands. The latest trailing twelve months (TTM) revenue stands at ₹326 Cr, affirming a solid upward trajectory. However, the quarterly performance reveals some volatility; for instance, Q2 FY 2025 recorded ₹94.16 Cr, a notable increase from ₹71.17 Cr in Q1 FY 2025, indicating strong seasonal patterns. Such fluctuations could be indicative of both opportunities and challenges, as the company navigates a landscape where demand can be unpredictable.
Profitability and Efficiency Metrics
When examining Genesys’s profitability, one cannot overlook its operating profit margin (OPM), which stood impressively at 46% in FY 2025, reflecting effective cost management and operational efficiency. However, the journey to this figure has not been linear; the OPM dipped to 16.79% in Q1 FY 2024, showcasing that the company has faced challenges in maintaining margins consistently. The net profit for FY 2025 was reported at ₹56 Cr, translating to an earnings per share (EPS) of ₹14.12, a significant rebound from the losses recorded in previous years. The return on equity (ROE) of 10.12% and return on capital employed (ROCE) of 15.53% signal that the company is generating adequate returns on shareholders’ investments, although these figures could be seen as modest compared to industry benchmarks. Overall, while profitability appears strong, the fluctuating margins highlight the need for sustained vigilance in cost management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Genesys International presents a mixed picture of strength and caution. Total borrowings have risen to ₹147 Cr, yet this remains manageable given the company’s total assets of ₹920 Cr. The current ratio of 2.41 indicates a comfortable liquidity position, allowing for potential short-term obligations without undue stress. Reserves have seen a commendable increase, from ₹387 Cr in FY 2023 to ₹536 Cr in FY 2025, providing a buffer against market volatility. However, the price-to-book value ratio of 5.15 suggests that the stock might be trading at a premium, which could raise concerns for value-oriented investors. While the interest coverage ratio of 16.68x is strong, indicating that the company can cover its interest obligations comfortably, the rising borrowings warrant a closer look as they could affect future financial flexibility.
Shareholding Pattern and Investor Confidence
Investor confidence in Genesys International is reflected in its shareholding pattern. Promoter holdings have declined to 31.55%, with the public holding now comprising 62.27% of total shares, which might indicate a shift towards greater retail participation. While this broad public ownership can enhance market liquidity, the declining promoter stake could raise questions about long-term commitment from the founding team. Foreign institutional investors (FIIs) have reduced their stake to 4.69%, a trend that could be a red flag for some investors, as it suggests cautious sentiment from larger global players. On the other hand, the growing number of shareholders—now at 45,192—points to increasing retail interest, which is often seen as a positive sign for a company’s future. This dynamic could create a supportive environment for price stability, provided the company continues to deliver on its operational promises.
Outlook, Risks, and Final Insight
Looking ahead, Genesys International stands at a crossroads. The company’s impressive revenue growth and strong profitability metrics suggest a healthy operational foundation. However, risks abound. The volatility in quarterly sales and margins could impact investor sentiment, especially if the company fails to maintain consistent performance. Additionally, the rising borrowings may pose a challenge if market conditions shift unfavorably, making debt servicing more cumbersome. As investors weigh these factors, understanding Genesys’s strategic direction becomes crucial. The growth potential in the IT consulting space remains robust, but it will be essential for the company to leverage its strengths while addressing its weaknesses. In a climate where technological advancements occur rapidly, Genesys must remain agile to capitalize on opportunities while mitigating risks effectively. Investors should keep a close watch on how the company’s financial health evolves against the backdrop of industry trends and economic conditions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesys International Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Visesh Infotecnics Ltd | 125 Cr. | 0.33 | / | 1.11 | 0.00 % | 2.21 % | 2.23 % | 1.00 | |
| Mudunuru Ltd | 46.4 Cr. | 14.7 | 14.7/4.43 | 0.20 | 0.00 % | 27.0 % | 90.7 % | 2.00 | |
| Naapbooks Ltd | 164 Cr. | 152 | 194/99.8 | 25.1 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 25.0 Cr. | 196 | 310/140 | 17.9 | 26.7 | 0.51 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.04 Cr. | 1.03 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Industry Average | 20,343.17 Cr | 557.14 | 87.21 | 123.78 | 0.55% | 14.89% | 20.93% | 6.84 |
All Competitor Stocks of Genesys International Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.69 | 37.38 | 54.43 | 46.62 | 34.55 | 33.19 | 59.34 | 71.17 | 55.76 | 72.02 | 89.09 | 94.16 | 70.87 |
| Expenses | 30.95 | 26.42 | 35.07 | 30.30 | 28.75 | 25.49 | 28.56 | 34.92 | 35.35 | 42.64 | 46.52 | 44.39 | 41.37 |
| Operating Profit | 11.74 | 10.96 | 19.36 | 16.32 | 5.80 | 7.70 | 30.78 | 36.25 | 20.41 | 29.38 | 42.57 | 49.77 | 29.50 |
| OPM % | 27.50% | 29.32% | 35.57% | 35.01% | 16.79% | 23.20% | 51.87% | 50.93% | 36.60% | 40.79% | 47.78% | 52.86% | 41.63% |
| Other Income | 1.37 | 1.93 | 1.79 | 1.41 | 0.93 | 1.11 | 2.53 | 0.46 | 1.41 | 1.00 | 1.84 | 0.11 | 1.27 |
| Interest | 0.54 | 0.56 | 0.35 | 1.22 | 0.67 | 0.72 | 1.09 | 1.43 | 1.24 | 1.88 | 2.58 | 3.08 | 3.18 |
| Depreciation | 8.14 | 8.90 | 9.30 | 10.86 | 11.30 | 10.94 | 11.06 | 11.18 | 11.80 | 12.25 | 15.69 | 15.29 | 15.43 |
| Profit before tax | 4.43 | 3.43 | 11.50 | 5.65 | -5.24 | -2.85 | 21.16 | 24.10 | 8.78 | 16.25 | 26.14 | 31.51 | 12.16 |
| Tax % | 55.53% | 5.83% | 32.70% | 64.42% | 4.39% | 20.70% | 25.71% | 38.63% | 39.64% | 31.69% | 20.73% | 39.73% | 42.60% |
| Net Profit | 1.97 | 3.23 | 7.73 | 2.00 | -5.46 | -3.43 | 15.73 | 14.79 | 5.30 | 11.09 | 20.71 | 19.00 | 6.98 |
| EPS in Rs | 1.36 | 1.30 | 2.13 | 0.57 | -1.41 | -0.87 | 4.19 | 3.76 | 1.36 | 2.83 | 5.20 | 4.76 | 1.71 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Genesys International Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.87 Cr.. The value appears to be declining and may need further review. It has decreased from 94.16 Cr. (Mar 2025) to 70.87 Cr., marking a decrease of 23.29 Cr..
- For Expenses, as of Jun 2025, the value is 41.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.39 Cr. (Mar 2025) to 41.37 Cr., marking a decrease of 3.02 Cr..
- For Operating Profit, as of Jun 2025, the value is 29.50 Cr.. The value appears to be declining and may need further review. It has decreased from 49.77 Cr. (Mar 2025) to 29.50 Cr., marking a decrease of 20.27 Cr..
- For OPM %, as of Jun 2025, the value is 41.63%. The value appears to be declining and may need further review. It has decreased from 52.86% (Mar 2025) to 41.63%, marking a decrease of 11.23%.
- For Other Income, as of Jun 2025, the value is 1.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Mar 2025) to 1.27 Cr., marking an increase of 1.16 Cr..
- For Interest, as of Jun 2025, the value is 3.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.08 Cr. (Mar 2025) to 3.18 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 15.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.29 Cr. (Mar 2025) to 15.43 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.16 Cr.. The value appears to be declining and may need further review. It has decreased from 31.51 Cr. (Mar 2025) to 12.16 Cr., marking a decrease of 19.35 Cr..
- For Tax %, as of Jun 2025, the value is 42.60%. The value appears to be increasing, which may not be favorable. It has increased from 39.73% (Mar 2025) to 42.60%, marking an increase of 2.87%.
- For Net Profit, as of Jun 2025, the value is 6.98 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 6.98 Cr., marking a decrease of 12.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.71. The value appears to be declining and may need further review. It has decreased from 4.76 (Mar 2025) to 1.71, marking a decrease of 3.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:19 am
| Metric | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 60 | 47 | 64 | 114 | 115 | 112 | 80 | 120 | 181 | 198 | 311 | 326 |
| Expenses | 42 | 47 | 40 | 48 | 78 | 96 | 98 | 81 | 92 | 122 | 117 | 168 | 175 |
| Operating Profit | 53 | 13 | 7 | 16 | 36 | 19 | 13 | -2 | 28 | 59 | 81 | 143 | 151 |
| OPM % | 56% | 21% | 16% | 25% | 32% | 17% | 12% | -2% | 23% | 32% | 41% | 46% | 46% |
| Other Income | -1 | 2 | 6 | 3 | 4 | 3 | 4 | -30 | -42 | 6 | 5 | 4 | 4 |
| Interest | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 5 | 10 | 11 |
| Depreciation | 7 | 8 | 7 | 13 | 14 | 19 | 21 | 19 | 19 | 37 | 44 | 55 | 59 |
| Profit before tax | 45 | 5 | 5 | 5 | 24 | 0 | -7 | -54 | -36 | 25 | 37 | 83 | 86 |
| Tax % | -1% | 11% | 6% | -41% | 28% | 1,108% | -23% | -5% | 11% | 40% | 42% | 32% | |
| Net Profit | 46 | 4 | 2 | 6 | 17 | -4 | -5 | -52 | -40 | 15 | 22 | 56 | 58 |
| EPS in Rs | 15.42 | 1.43 | 0.73 | 2.11 | 5.50 | 1.73 | 0.61 | -13.75 | 4.28 | 5.05 | 5.58 | 14.12 | 14.50 |
| Dividend Payout % | 8% | 9% | 17% | 6% | 2% | 7% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 183.33% | -123.53% | -25.00% | -940.00% | 23.08% | 137.50% | 46.67% | 154.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | -16.67% | -306.86% | 98.53% | -915.00% | 963.08% | 114.42% | -90.83% | 107.88% |
Genesys International Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 38% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 98% |
| 3 Years: | -3% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 63% |
| 3 Years: | 1% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 4:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:16 am
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 19 | 20 | 20 | 21 |
| Reserves | 126 | 193 | 195 | 152 | 209 | 208 | 197 | 158 | 189 | 387 | 469 | 536 | 662 |
| Borrowings | 2 | 12 | 14 | 22 | 24 | 26 | 16 | 14 | 26 | 39 | 60 | 122 | 147 |
| Other Liabilities | 23 | 25 | 37 | 135 | 136 | 134 | 136 | 117 | 88 | 61 | 86 | 100 | 90 |
| Total Liabilities | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 | 920 |
| Fixed Assets | 46 | 21 | 22 | 179 | 217 | 208 | 203 | 194 | 138 | 157 | 156 | 128 | 265 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 65 | 113 | 156 | 4 |
| Investments | 8 | 122 | 156 | 25 | 11 | 11 | 15 | 8 | 6 | 51 | 0 | 0 | 0 |
| Other Assets | 111 | 101 | 84 | 120 | 157 | 165 | 147 | 102 | 156 | 232 | 366 | 495 | 652 |
| Total Assets | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 | 920 |
Below is a detailed analysis of the balance sheet data for Genesys International Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2025) to 21.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 662.00 Cr.. The value appears strong and on an upward trend. It has increased from 536.00 Cr. (Mar 2025) to 662.00 Cr., marking an increase of 126.00 Cr..
- For Borrowings, as of Sep 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 122.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 25.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 90.00 Cr.. The value appears to be improving (decreasing). It has decreased from 100.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 920.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 778.00 Cr. (Mar 2025) to 920.00 Cr., marking an increase of 142.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 265.00 Cr.. The value appears strong and on an upward trend. It has increased from 128.00 Cr. (Mar 2025) to 265.00 Cr., marking an increase of 137.00 Cr..
- For CWIP, as of Sep 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 152.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 652.00 Cr.. The value appears strong and on an upward trend. It has increased from 495.00 Cr. (Mar 2025) to 652.00 Cr., marking an increase of 157.00 Cr..
- For Total Assets, as of Sep 2025, the value is 920.00 Cr.. The value appears strong and on an upward trend. It has increased from 778.00 Cr. (Mar 2025) to 920.00 Cr., marking an increase of 142.00 Cr..
Notably, the Reserves (662.00 Cr.) exceed the Borrowings (147.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 51.00 | 1.00 | -7.00 | -6.00 | 12.00 | -7.00 | -3.00 | -16.00 | 2.00 | 20.00 | 21.00 | 21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Working Capital Days | 172 | 326 | 172 | 105 | 99 | 215 | 223 | 126 | 82 | 212 | 269 | 291 |
| ROCE % | 41% | 3% | 3% | 8% | 1% | -1% | -7% | 4% | 7% | 8% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 14.14 | 5.78 | 5.44 | 4.28 | -13.77 |
| Diluted EPS (Rs.) | 14.03 | 5.74 | 5.29 | 4.28 | -13.34 |
| Cash EPS (Rs.) | 27.92 | 16.72 | 13.81 | -6.55 | -10.57 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Revenue From Operations / Share (Rs.) | 78.14 | 50.14 | 47.97 | 38.14 | 25.48 |
| PBDIT / Share (Rs.) | 36.80 | 21.64 | 17.18 | 9.83 | -0.49 |
| PBIT / Share (Rs.) | 22.98 | 10.39 | 7.33 | 3.74 | -6.51 |
| PBT / Share (Rs.) | 20.77 | 9.40 | 6.62 | -11.44 | -17.43 |
| Net Profit / Share (Rs.) | 14.10 | 5.47 | 3.95 | -12.65 | -16.59 |
| NP After MI And SOA / Share (Rs.) | 14.13 | 5.58 | 5.05 | 4.28 | -13.75 |
| PBDIT Margin (%) | 47.09 | 43.16 | 35.81 | 25.78 | -1.95 |
| PBIT Margin (%) | 29.40 | 20.72 | 15.27 | 9.79 | -25.53 |
| PBT Margin (%) | 26.58 | 18.75 | 13.79 | -29.98 | -68.43 |
| Net Profit Margin (%) | 18.03 | 10.90 | 8.24 | -33.17 | -65.09 |
| NP After MI And SOA Margin (%) | 18.07 | 11.13 | 10.53 | 11.21 | -53.96 |
| Return on Networth / Equity (%) | 10.12 | 4.51 | 4.70 | 6.54 | -24.77 |
| Return on Capital Employeed (%) | 15.53 | 7.81 | 6.33 | 4.76 | -7.59 |
| Return On Assets (%) | 7.22 | 3.47 | 3.77 | 4.17 | -14.11 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.04 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.10 | 0.07 | 0.09 | 0.03 |
| Asset Turnover Ratio (%) | 0.44 | 0.34 | 0.43 | 0.41 | 0.23 |
| Current Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Quick Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Interest Coverage Ratio (X) | 16.68 | 21.89 | 24.33 | 12.45 | -0.53 |
| Interest Coverage Ratio (Post Tax) (X) | 7.39 | 6.53 | 6.60 | 3.19 | -6.06 |
| Enterprise Value (Cr.) | 2956.65 | 2312.97 | 1258.23 | 1817.61 | 404.10 |
| EV / Net Operating Revenue (X) | 9.51 | 11.67 | 6.95 | 15.19 | 5.08 |
| EV / EBITDA (X) | 20.18 | 27.03 | 19.40 | 58.93 | -260.36 |
| MarketCap / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| Price / BV (X) | 5.15 | 4.78 | 3.06 | 8.73 | 1.84 |
| Price / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.13 |
After reviewing the key financial ratios for Genesys International Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 14.14. This value is within the healthy range. It has increased from 5.78 (Mar 24) to 14.14, marking an increase of 8.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 14.03. This value is within the healthy range. It has increased from 5.74 (Mar 24) to 14.03, marking an increase of 8.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.92. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 27.92, marking an increase of 11.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.14. It has increased from 50.14 (Mar 24) to 78.14, marking an increase of 28.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.80. This value is within the healthy range. It has increased from 21.64 (Mar 24) to 36.80, marking an increase of 15.16.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.98. This value is within the healthy range. It has increased from 10.39 (Mar 24) to 22.98, marking an increase of 12.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.77. This value is within the healthy range. It has increased from 9.40 (Mar 24) to 20.77, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 14.10, marking an increase of 8.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 14.13. This value is within the healthy range. It has increased from 5.58 (Mar 24) to 14.13, marking an increase of 8.55.
- For PBDIT Margin (%), as of Mar 25, the value is 47.09. This value is within the healthy range. It has increased from 43.16 (Mar 24) to 47.09, marking an increase of 3.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.40. This value exceeds the healthy maximum of 20. It has increased from 20.72 (Mar 24) to 29.40, marking an increase of 8.68.
- For PBT Margin (%), as of Mar 25, the value is 26.58. This value is within the healthy range. It has increased from 18.75 (Mar 24) to 26.58, marking an increase of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 18.03. This value exceeds the healthy maximum of 10. It has increased from 10.90 (Mar 24) to 18.03, marking an increase of 7.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has increased from 11.13 (Mar 24) to 18.07, marking an increase of 6.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.12. This value is below the healthy minimum of 15. It has increased from 4.51 (Mar 24) to 10.12, marking an increase of 5.61.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.53. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 15.53, marking an increase of 7.72.
- For Return On Assets (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 3.47 (Mar 24) to 7.22, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.19, marking an increase of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.34 (Mar 24) to 0.44, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Quick Ratio (X), as of Mar 25, the value is 2.41. This value exceeds the healthy maximum of 2. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 21.89 (Mar 24) to 16.68, marking a decrease of 5.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 7.39, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,956.65. It has increased from 2,312.97 (Mar 24) to 2,956.65, marking an increase of 643.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has decreased from 11.67 (Mar 24) to 9.51, marking a decrease of 2.16.
- For EV / EBITDA (X), as of Mar 25, the value is 20.18. This value exceeds the healthy maximum of 15. It has decreased from 27.03 (Mar 24) to 20.18, marking a decrease of 6.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For Price / BV (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has increased from 4.78 (Mar 24) to 5.15, marking an increase of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesys International Corporation Ltd:
- Net Profit Margin: 18.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.53% (Industry Average ROCE: 14.89%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.12% (Industry Average ROE: 20.93%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.4 (Industry average Stock P/E: 87.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | 73-A, SDF-III, SEEPZ, Mumbai Maharashtra 400096 | investors@igenesys.com http://www.igenesys.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sajid Malik | Chairman & Managing Director |
| Ms. Bharti Sinha | Independent Director |
| Mr. Manish Patel | Independent Director |
| Mr. Ajay Aggarwal | Independent Director |
| Mr. Omprakash Hemrajani | Director |
| Dr. Yogita Shukla | Director |
FAQ
What is the intrinsic value of Genesys International Corporation Ltd?
Genesys International Corporation Ltd's intrinsic value (as of 09 December 2025) is 439.37 which is 2.66% higher the current market price of 428.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,785 Cr. market cap, FY2025-2026 high/low of 1,055/390, reserves of ₹662 Cr, and liabilities of 920 Cr.
What is the Market Cap of Genesys International Corporation Ltd?
The Market Cap of Genesys International Corporation Ltd is 1,785 Cr..
What is the current Stock Price of Genesys International Corporation Ltd as on 09 December 2025?
The current stock price of Genesys International Corporation Ltd as on 09 December 2025 is 428.
What is the High / Low of Genesys International Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesys International Corporation Ltd stocks is 1,055/390.
What is the Stock P/E of Genesys International Corporation Ltd?
The Stock P/E of Genesys International Corporation Ltd is 30.4.
What is the Book Value of Genesys International Corporation Ltd?
The Book Value of Genesys International Corporation Ltd is 164.
What is the Dividend Yield of Genesys International Corporation Ltd?
The Dividend Yield of Genesys International Corporation Ltd is 0.00 %.
What is the ROCE of Genesys International Corporation Ltd?
The ROCE of Genesys International Corporation Ltd is 15.0 %.
What is the ROE of Genesys International Corporation Ltd?
The ROE of Genesys International Corporation Ltd is 10.8 %.
What is the Face Value of Genesys International Corporation Ltd?
The Face Value of Genesys International Corporation Ltd is 5.00.